Literature DB >> 11927937

Not just research tools--proteasome inhibitors offer therapeutic promise.

Alfred L Goldberg, Kenneth Rock.   

Abstract

Keywords:  Non-programmatic

Mesh：

Substances：

Year:  2002        PMID： 11927937     DOI： 10.1038/nm0402-338

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  20 in total

1.  Androgen-regulated formation and degradation of gap junctions in androgen-responsive human prostate cancer cells.

Authors:  Shalini Mitra; Lakshmanan Annamalai; Souvik Chakraborty; Kristen Johnson; Xiao-Hong Song; Surinder K Batra; Parmender P Mehta
Journal:  Mol Biol Cell       Date:  2006-10-18       Impact factor: 4.138

2.  Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.

Authors:  Kai Sun; Danice E C Wilkins; Miriam R Anver; Thomas J Sayers; Angela Panoskaltsis-Mortari; Bruce R Blazar; Lisbeth A Welniak; William J Murphy
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

3.  Fundamental reaction pathway for peptide metabolism by proteasome: insights from first-principles quantum mechanical/molecular mechanical free energy calculations.

Authors:  Donghui Wei; Lei Fang; Mingsheng Tang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2013-10-10       Impact factor: 2.991

Review 4.  Proteasome inhibition: a new anti-inflammatory strategy.

Authors:  Peter J Elliott; Thomas Matthias Zollner; Wolf-Henning Boehncke
Journal:  J Mol Med (Berl)       Date:  2003-03-26       Impact factor: 4.599

5.  Fundamental reaction pathway and free energy profile for inhibition of proteasome by Epoxomicin.

Authors:  Donghui Wei; Beilei Lei; Mingsheng Tang; Chang-Guo Zhan
Journal:  J Am Chem Soc       Date:  2012-06-14       Impact factor: 15.419

6.  Total synthesis of TMC-95A and -B via a new reaction leading to Z-enamides. Some preliminary findings as to SAR.

Authors:  Songnian Lin; Zhi-Qiang Yang; Benjamin H B Kwok; Michael Koldobskiy; Craig M Crews; Samuel J Danishefsky
Journal:  J Am Chem Soc       Date:  2004-05-26       Impact factor: 15.419

7.  Macrophages transmit human immunodeficiency virus type 1 products to CD4-negative cells: involvement of matrix metalloproteinase 9.

Authors:  Claudia Muratori; Antonella Sistigu; Eliana Ruggiero; Mario Falchi; Ilaria Bacigalupo; Clelia Palladino; Elena Toschi; Maurizio Federico
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

8.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

9.  Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity.

Authors:  Zhi-Qiang Yang; Benjamin H B Kwok; Songnian Lin; Michael A Koldobskiy; Craig M Crews; Samuel J Danishefsky
Journal:  Chembiochem       Date:  2003-06-06       Impact factor: 3.164

10.  Identifying the optimal dose of ritonavir in the treatment of malignancies.

Authors:  Emad Y Moawad
Journal:  Metab Brain Dis       Date:  2013-11-19       Impact factor: 3.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.